Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection
Trial details
- Registry ID
- NCT04980482
- Drugs studied
- AB-729, Peg-IFNα-2a
TrialRedline tracks 1 clinical trial sponsored by Arbutus Biopharma Corporation: 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B InfectionNCT04980482 | AB-729, Peg-IFNα-2a | Completed | 2025-03-13Actual |
Names as written in the registry records.
NCT04980482 · Arbutus Biopharma Corporation
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: The frequency and severity of treatment emergent adverse events (TEAEs), discontinuations due to adverse events (AEs), and laboratory abnormalities after dosing with AB-729 plus Peg-IFNα-2a. After: Measure: The Frequency and Severity of Treatment Emergent Adverse Events (TEAEs), Discontinuations Due to AEs and Lab Abnormalities After Dosing With AB-729 Plus Peg-IFNα-2a.